MVD — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL7261083	0.53	6/20
SCHEMBL472232	0.46	6/20
SCHEMBL2713029	0.57	5/20
SCHEMBL12323052	0.46	5/20
SCHEMBL7025762	0.45	5/20
SCHEMBL11952600	0.76	4/20
Diphosphomelavonate (SCHEMBL183248)	0.64	4/20
Diphosphomelavonate (SCHEMBL3272270)	0.64	4/20
SCHEMBL4326443	0.64	4/20
SCHEMBL4657446	0.57	4/20
SCHEMBL7531145	0.55	4/20
Edetic Acid (SCHEMBL3881110)	0.54	4/20
Edetic Acid (SCHEMBL5073281)	0.54	4/20
SCHEMBL11952592	0.54	4/20
SCHEMBL3449173	0.51	4/20
SCHEMBL1542080	0.50	4/20
SCHEMBL2575780	0.50	4/20
SCHEMBL2585075	0.50	4/20
SCHEMBL10755891	0.50	4/20
SCHEMBL63984	0.48	4/20

Clinical trials — most relevant to MVD by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Vitamin k1 and Its Relation to Vascular Calcification in Hemodialysis Patients	PHASE4	COMPLETED
Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations	PHASE3	COMPLETED
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer	PHASE2	COMPLETED
Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene	PHASE2	COMPLETED
Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients	PHASE2	COMPLETED
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer	PHASE2	COMPLETED
Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms	PHASE1/PHASE2	RECRUITING
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
Clinical Implication of Bone Marrow Perfusion Patterns Imaged by Dynamic MRI in Multiple Myeloma	nan	UNKNOWN
89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma	nan	UNKNOWN
Genetics of Arteriovenous Malformations	nan	UNKNOWN
Mayo AVC Registry and Biobank	nan	RECRUITING
Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.	nan	COMPLETED
CADASIL Disease Discovery	nan	COMPLETED
Genetics and Pain Severity in Sickle Cell Disease	nan	COMPLETED
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte	nan	COMPLETED
Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer	nan	UNKNOWN
Evaluation of Nidus Occlusion After Gamma Knife Radiosurgery of Cerebral Arteriovenous Malformations Using Magnetic Resonance Imaging	nan	COMPLETED
Studies on the Adaptive Responses to Hypoxia	nan	COMPLETED
Study About Patients Using Copper Intrauterine Device	nan	COMPLETED
Pathophysiology of Paget's Disease of Bone	nan	COMPLETED
Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B	nan	COMPLETED
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease	nan	COMPLETED
Markers and Mechanisms of Macrovascular Disease in IDDM	nan	COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Impact of Von Willebrand Factor and Its Multimers on Angiogenesis	nan	UNKNOWN
Tamoxifen Pharmacogenetics in Asian Breast Cancer Women	nan	UNKNOWN
Validation of Laser Doppler Flowmetry to Identify Allergic Rhinitis Patients With Pharmacogenetic Alterations in Histamine Metabolism	nan	COMPLETED
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions	nan	RECRUITING
Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MVD binder may also engage these)

Protein	Name	Similarity
Q99JF5	—	1.000	Q99JF5 →
Q0P570	—	1.000	Q0P570 →
Q62967	—	1.000	Q62967 →
Q751D8	—	0.996	Q751D8 →
D0EAP4	—	0.995	D0EAP4 →
Q5U403	—	0.995	Q5U403 →
G9BIY1	—	0.994	G9BIY1 →
O13963	—	0.993	O13963 →
I1S130	—	0.993	I1S130 →
P32377	—	0.991	P32377 →
Q4WNV9	—	0.990	Q4WNV9 →
F4JCU3	—	0.990	F4JCU3 →
O23722	—	0.990	O23722 →
F8QQQ7	—	0.989	F8QQQ7 →
A0A1D8PC43	—	0.986	A0A1D8PC43 →
Q4Q0M0	—	0.984	Q4Q0M0 →
I1RZD0	—	0.984	I1RZD0 →
P17423	—	0.983	P17423 →
J9VU26	—	0.983	J9VU26 →
Q4WV38	—	0.982	Q4WV38 →
Q54YQ9	—	0.982	Q54YQ9 →
P10351	—	0.981	P10351 →
O23461	—	0.981	O23461 →
Q38CB5	—	0.981	Q38CB5 →
Q38A34	—	0.981	Q38A34 →
O88428	—	0.981	O88428 →
Q84WW3	—	0.981	Q84WW3 →
Q38970	—	0.981	Q38970 →
P43284	—	0.981	P43284 →
P27967	—	0.980	P27967 →